Lior Brimberg is assistant professor of neuroimmunology at the Center for Autoimmune and Musculoskeletal Disorders at the Feinstein Institutes for Medical Research in Manhasset, New York.
Lior Brimberg
Assistant professor
Feinstein Institutes for Medical Research
From this contributor
Maternal anti-brain antibodies may play a role in autism
Maternal antibodies that attack fetal brain proteins could underlie some cases of autism, says immunologist Betty Diamond.
Maternal anti-brain antibodies may play a role in autism
By
Betty Diamond, Peter Gregersen, Lior Brimberg
21 February 2012 | 6 min read
Explore more from The Transmitter
Latest iteration of U.S. federal autism committee comes under fire
The new panel “represents a radical departure from all past rosters,” says autism researcher Helen Tager-Flusberg.
Latest iteration of U.S. federal autism committee comes under fire
The new panel “represents a radical departure from all past rosters,” says autism researcher Helen Tager-Flusberg.
By
Angie Voyles Askham
29 January 2026 | 9 min read
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
By
Holly Barker
29 January 2026 | 4 min read
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
By
Paul Middlebrooks
28 January 2026 | 1 min read